Phase II Study of Single-Agent Bevacizumab in Patients With Epithelial Ovarian, Primary Peritoneal Serous or Fallopian Tube Cancer Who Have Recurred After Prior Therapy With Maintenance Bevacizumab

Trial Profile

Phase II Study of Single-Agent Bevacizumab in Patients With Epithelial Ovarian, Primary Peritoneal Serous or Fallopian Tube Cancer Who Have Recurred After Prior Therapy With Maintenance Bevacizumab

Discontinued
Phase of Trial: Phase II

Latest Information Update: 01 Jun 2017

At a glance

  • Drugs Bevacizumab (Primary)
  • Indications Endometrial cancer; Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 16 Jun 2014 Status changed from suspended to discontinued as reported by ClinicalTrials.gov record.
    • 17 Nov 2010 Status changed from recruiting to suspended as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top